Takeda, Arthritis Foundation launch gout awareness effort

Share this article:
Takeda, Arthritis Foundation launch gout awareness effort
Takeda, Arthritis Foundation launch gout awareness effort

Takeda Pharmaceuticals North America and the Arthritis Foundation launched a gout awareness campaign featuring TV and radio PSAs airing nationally, along with a website, www.goutliving.org.

It's the first-ever high-profile education effort around the disease, said Takeda and the Arthritis Foundation, and it aims to communicate that “ living with the disease “doesn't have to mean missing out on life's special moments.”

The website includes an “attack tracker,” points for discussion with physicians, and a glossary of medical terms.

Takeda's Uloric won FDA approval for chronic management of hyperuricemia in patients with gout last year, becoming the first new gout drug to win approval in four decades.

The PSAs were produced by M Street Creative. PR is being handled by Ketchum.

Coincidentally, the campaign launched a day before Savient's gout drug Krystexxa (pegloticase) won FDA approval as a second-line treatment. Krystexxa has a different mechanism of action than xanthine oxidase inhibitors like Uloric, making it a potentially valuable treatment in patients for whom conventional treatments like the Takeda drug don't work. However, Krystexxa also carries a black box warning of possible severe allergic reaction experienced by a quarter of all patients in clinical trials.

Share this article:

Email Newsletters

More in News

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.

Shire, AbbVie join forces for $55B

Shire, AbbVie join forces for $55B

The deal includes a $1.6-billion fee if AbbVie tries to walk away.

Next target for hep. C drugmakers: co-infections

Next target for hep. C drugmakers: co-infections

An international AIDS conference this weekend kicked off a new battle in the war against hepatitis C: demonstrating high cure rates in those who are co-infected.